Evidence map›Paper›PMID 40164335›Full record

ArticleJournal of lipid research2025

Elevated high-density lipoprotein triglycerides increase atherosclerotic risk.

Weifang Liu, Shaoze Chen, Chengzhang Yang, Fang Lei, Xuewei Huang, Xingyuan Zhang, Tao Sun, Lijin Lin, Chuansen Wang, Yuanyuan Cao and 3 more

Abstract read
In one paragraph

Article in Journal of lipid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weifang LiuDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; State Key Laboratory of New Drug Discovery and Development for Major Diseases, Gannan Medical University, Ganzhou, China; Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China.
Shaoze ChenDepartment of Cardiology, Huanggang Central Hospital of Yangtze University, Huanggang, China.
Chengzhang YangDepartment of Cardiology, Huanggang Central Hospital of Yangtze University, Huanggang, China.
Fang LeiMedical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xuewei HuangDepartment of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China.
Xingyuan ZhangSchool of Basic Medical Sciences, Wuhan University, Wuhan, China.
Tao SunDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Lijin LinDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Chuansen WangDepartment of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Yuanyuan CaoMedical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
Zhi-Gang SheDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; State Key Laboratory of New Drug Discovery and Development for Major Diseases, Gannan Medical University, Ganzhou, China; Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China. Electronic address: zgshe@whu.edu.cn.
Xuan XiaoDepartment of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. Electronic address: xiaoxuan1111@whu.edu.cn.
Hongliang LiDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; State Key Laboratory of New Drug Discovery and Development for Major Diseases, Gannan Medical University, Ganzhou, China; Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, China. Electronic address: lihl@whu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between high-density lipoprotein (HDL) and atherosclerotic risk remains incompletely elucidated, potentially due to the inherent heterogeneity of HDL particles. Hypertriglyceridemia is associated with alterations in HDL composition. This study investigated the impact of elevated triglycerides (TG) on HDL and its association with coronary artery disease (CAD) risk using a large prospective cohort study and Mendelian randomization (MR). We found that elevated TG was associated with reduced HDL particle size, decreased concentrations of HDL components, and increased triglycerides in HDL (HDL-TG) (all P for trend < 0.001). The protective effects of HDL particle concentration and HDL cholesterol on CAD are attenuated with increasing serum TG levels. An independent and positive association between HDL-TG levels and incident CAD events (hazard ratio [HR] per 1 standard deviation increase: 1.066, 95% CI: 1.052-1.080, P < 0.001) was confirmed even after adjustment for established cardiovascular disease risk factors. MR analyses supported a causal role for HDL-TG in CAD development (inverse-variance weighted [IVW] method: odds ratios [ORs] of 1.120 (95% CI: 1.053-1.192, P < 0.001) and 1.141 (95% CI: 1.032-1.263, P = 0.010) for dataset groups 1 and 2, respectively). Drug-target MR analyses suggested a potential association between omega-3 fatty acids (OM3-FA) and lower HDL-TG levels, with LPL and DGAT2 as key pharmacological targets. Our findings suggest that elevated TG contributes to adverse alterations in HDL, elevating CAD risk. HDL-TG is an independent positive risk factor for CAD and a potential causal contributor to CAD development. OM3-FA supplementation may offer a therapeutic strategy for mitigating the CAD risk associated with elevated HDL-TG.

Indexed as

AtherosclerosisCoronary Artery DiseaseLipoproteins, HDLTriglyceridesAgedCholesterol, HDLFemaleHumansMaleMendelian Randomization AnalysisMiddle AgedProspective StudiesRisk FactorsCholesterol, HDLHDL-triglycerideLipoproteins, HDLTriglyceridescoronary artery diseasehigh-density lipoproteinmendelian randomizationomega-3 fatty acidstriglycerides in high-density lipoprotein

Identifiers

PMID40164335
PMCPMC12088758

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.